Revista de la OFIL
ISSN 1699-714X ISSN 1131-9429
ARIAS RICO, R GALVEZ ALVAREZ, N. Comparison of Lysine and Arginine content in amino acid parenteral formulas approved in Spain. []. , 33, 1, pp.91-94. 27--2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2023000100016.
Introduction:
Peptide Receptor Radionuclide Therapy represents an effective therapeutic strategy against neuroendocrine tumors, but it is not without serious adverse effects such as nephrotoxicity. In order to prevent this nephrotoxicity, Lysine and Arginine amino acid solutions are used. The objectives of this article are to to know the content of LLysine, L-Arginine and the osmolarity in commercial amino acid solutions authorized in Spain until march 2021 and to compare their composition with the characteristics of the nephroprotective solutions indicated in the Lutetium technical data sheet.
Methods:
Review of all the technical sheets of all those amino acid solutions that were marketed in Spain. Commercial presentations with other macronutrients or electrolytes that do not have a stability or solution conservation function were excluded.
Results:
From the 23,658 commercial presentations as of march 2021, 90 parenteral nutrition solutions were selected. After this first selection, 18 commercial presentations met the inclusion criteria. Of the included solutions, when the content was extrapolated to a maximum volume of 2000 ml, they met the objectives of L-Lysine and L-Arginine. The content varied between solutions and was mostly the highest content in L-Arginine. The solutions studied had a high osmolarity.
Discussion:
Using a maximum volume of 2000 ml, most of the solutions included in the study fulfilled the requirements of the content of L-Lysine and L-Arginine indicated in the technical data sheet, although there may be problems of administration by peripheral route to the have a high osmolarity. The fact that they include other amino acids could lead to other types of adverse effects such as gastrointestinal toxicity.
: Aminoacids; Lysine; Arginine; PRRT.